Key result
Benfluorex-induced valvulopathy progresses to extensive calcification and caseous mitral annular necrosis over 10 years.
Why the study?
Benfluorex is recognized to induce noncalcified restrictive valvular regurgitation, and the association of calcifications with benfluorex-induced valve heart disease is misknown.
Case Report (n=2)
No
Answers are grounded in this paper and cite their sources.
May progress to calcifications and necrosis after benfluorex; leaves open the full phenotypic spectrum of drug-induced valvular disease.
Benfluorex, an anorexigenic agent, is recognized to induce noncalcified restrictive valvular regurgitation. We report a well-documented case of a 73-year-old patient who developed heart failure with aortic and mitral regurgitation following benfluorex intake. Echocardiography and peroperative analysis found large mitral annular calcifications and aortic subvalvular calcifications. Pathology confirmed drug-induced valve heart disease (DIVHD). The presence of valvular apparatus calcification should not lead to diagnosis of degenerative valvular disease and a priori preclude the diagnosis of DIVHD.
No takes yet. Share an insight, caveat, or question.
Plurien et al. (2015) conducted a case report in Benfluorex-induced valvular heart disease (n=2). Benfluorex was evaluated on Progression to extensive valvular calcifications and caseous mitral annular calcification. Benfluorex-induced valvular heart disease progressed over 10 years to extensive valvular calcifications and caseous mitral annular necrosis in 2 female patients.
Synapse has enriched 10 related papers. Consider them for comparative context: